Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation
ConditionAtrial Fibrillation (AF)
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Luebeck
About this trial
To evaluate whether pre-treatment with semaglutide is superior to standard care in improving freedom from atrial fibrillation (AF) at 12 months following catheter ablation in patients with obesity and symptomatic AF undergoing first-time ablation.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age 18-80 years
Symptomatic paroxysmal or persistent AF eligible for first-time catheter ablation
Body mass index ≥30 kg/m or body mass index ≥28 kg/m plus ≥1 weight-related comorbidity
No prior treatment with glucacon-like peptide-1 receptor agonists
Disqualifiers
Current use of glucacon-like peptide-1 receptor agonists or dipeptidyl peptidase 4 inhibitors or use within the last 90 days prior to screening
Current antiobesity medication use or use within the last 90 days prior to screening
A self-reported change in body weight of >5 kg within 30 days before screening
History of bariatric surgery
Trial design
Design model
Parallel
Treatments tested in this trial
Semaglutide (SEMA)
DrugCatheter ablation for AF plus semaglutide (up to 2.4 mg weekly)
Treatment groups
240 Participants
are divided into 2 treatment groupsGroup A: Catheter ablation for atrial fibrillation plus semaglutideExperimental treatment 1 intervention
Group B: Catheter ablation for atrial fibrillation and no glucacon-like peptide-1 receptor therapyNo intervention 0 interventions
Trial outcomes
Primary outcomes
1
Freedom from atrial arrhythmia (AF/atrial flutter/atrial tachycardia >30 sec) at 12 months post-ablation (8-week-blanking period)
Time frame
12 monthsLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: